March 2009


	Standard Plan	Select Plan	Closed Plan

► BENEFIT DESIGN OPTIONS	A benefit plan with a one or two-tier structure that includes generic and brands. There is no difference between preferred and nonpreferred brands.	A benefit plan with a three-tier structure that includes generics, preferred brands and nonpreferred brands.	A benefit plan with a two-tier structure that includes generics and preferred brands. Nonpreferred brands are not covered.

► NEW DRUGS	Standard Plan	Select Plan	Closed Plan
Cinryze (C1 Inhibitor, IV inj)
Indicated for the routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE). Coverage determined by the benefit design chosen by the plan sponsor. Prior Authorization applies Specialty Pharmacy Program Effective April 1, 2009.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the brand copay. If the customer does not have the SPP it may be considered under the medical benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the preferred brand copay. If the customer does not have the SPP it may be considered under the medical benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the preferred brand copay. If the customer does not have the SPP it may be considered under the medical benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.
Xenazine (tetrabenazine)
Indicated for the treatment of abnormal movements associated with Huntington's disease. Coverage determined by the benefit design chosen by the plan sponsor. Prior Authorization applies Effective April 1, 2009.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.
Durezol (difluprednate ophthalmic emulsion)
A topical ophthlamic corticosteroid used to reduce inflammation after ocular surgery. Not in a limited category (Ophthalmic Steroids)	Brand copay.	Second tier, preferred brand copay.	Second tier, preferred brand copay.

► LINE EXTENSIONS	Standard Plan	Select Plan	Closed Plan
Keppra XR (levetiracetam SR tab)
An anticonvulsant used in the treatment of seizure disorder. New dose form reviewed. In a limited category (Anticonvulsants).	Brand copay.	Third tier, non-preferred brand copay.	Not covered.
Hycamtin (topotecan capsules)
The capsule form of Hycamtin is used in the treatment of patients with relapsed small cell lung cancer. New dose form reviewed. Not in a limited category (Antineoplastics)	Brand copay.	Second tier, preferred brand copay.	Second tier, preferred brand copay.
LoSeasonique (levonorgestrel/ ethinyl estradiol)
A low dose, extended cycle oral contraceptive. Quantity Limit applies In a limited category (Contraceptives)	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.
Astepro (azelastine HCl nasal spray)
An antihistamine used for the relief of symptoms of seasonal allergic rhinitis. Quantity Limit applies In a limited category (Allergy-Intranasal)	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.

► DRUG CLASS REVIEW	Standard Plan	Select Plan	Closed Plan
No changes from the February meetings

► PPL UPDATES	Standard Plan	Select Plan	Closed Plan
Avodart (dutasteride)
Used to treat the urinary symptoms of enlarging prostate. Avodart is being removed from preferred status. DACON edit applies In a limited category (Prostate)	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.
Ventolin HFA (albuterol sulfate)
Albuterol sulfate in metered dose inhaler form. Used in the prevention and relief of bronchospasm. Ventolin HFA is being removed from preferred status. Quantity Limit applies In a limited category (Asthma/COPD)	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.

► BRANDS WITH GENERICS AVAILABLE	Standard Plan	Select Plan	Closed Plan
Keppra Solution (levetiracetam oral solution)
Indicated for use in the treatment of seizure disorder. This medication is being removed from preferred status because the generic equivalent, levetiracetam oral solution, is available at the generic copay. In a limited category (Anticonvulsants)	Brand copay.	Third tier, non-preferred brand copay.	Not covered.
Zerit (stavudine)
Indicated for use in the treatment of Human Immunodeficiency Virus (HIV). Generic equivalent, stavudine, is available. Zerit remains at preferred status. Not in a limited category (Antivirals-HIV)	Brand copay.	Second tier, preferred brand copay.	Second tier, preferred brand copay.

► Clinical Programs: Prior Authorization	Standard Plan	Select Plan	Closed Plan
Ridaura (auranofin)
A disease modifying agent used in the treatment of rheumatoid arthritis (DMARD) Ridaura is being added to the Prior Authorization Program.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.

► Clinical Programs: Quantity Limits	Standard Plan	Select Plan	Closed Plan
sumatriptan
Quantity limits will be updated for "triptan" products in the Migraine category. Current QL of "tablet per copay" will be updated to "tablet per month."	Generic copay. Coverage determined by the benefit design chosen by the plan sponsor.	First tier, generic copay. Coverage determined by the benefit design chosen by the plan sponsor.	First tier, generic copay. Coverage determined by the benefit design chosen by the plan sponsor.
Relpax, Zomig
Quantity limits will be updated for "triptan" products in the Migraine category. Current QL of "tablet per copay" will be updated to "tablet per month."	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Amerge, Axert, Frova, Maxalt, Imitrex
Quantity limits will be updated for "triptan" products in the Migraine category. Current QL of "tablet per copay" will be updated to "tablet per month."	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.

► SPECIAL ANNOUNCEMENT It was reported in the February 1 edition of Pharmacy Passages (Class Review and PPL Updates) that Detrol and Detrol LA would be removed from preferred status, effective April 1, 2009. That change is no longer scheduled to take place.
Detrol, Detrol LA (tolterodine tartrate)
Indicated for the treatment of overactive bladder or urinary incontinence. Detrol / LA will remain at preferred status. DACON edit applies In a limited category (Genitourinary)	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.

	March 2009



Innoviant's Business Committee meets monthly to evaluate product status (tier placements) and new prescription products approved by the Food and Drug Administration (FDA). Decisions made by the Innoviant Business Committee are based on information and recommendations provided by Prescription Solutions' National Pharmacy & Therapeutics Committee (NPTC). The P&T is comprised of independent physician providers, affiliated plan physicians and pharmacists. The following table summarizes the decisions made at the February committee meetings. All changes are effective May 1, 2009 unless otherwise noted. Current information related to Innoviant and its offerings is available at www.innoviant.com. A copy of this newsletter can also be found on the website (http://www.innoviant.com/customers/publications/default.asp).